AOD-9604 and Cardiovascular Research: Metabolic Peptide Biology, Cardiac Protection and Vascular Mechanisms UK 2026

This article is intended for research and educational purposes only. AOD-9604 is a Research Use Only (RUO) compound supplied for laboratory investigation. It is not approved for human use, is not a medicine, and must not be administered to humans or animals outside of licenced research settings.

Introduction: AOD-9604 in the Context of Cardiovascular Metabolic Research

AOD-9604 (Anti-Obesity Drug 9604; hGH fragment 177-191) is a 15-amino acid C-terminal fragment of human growth hormone that retains the lipolytic and anti-lipogenic properties of GH while lacking the growth-promoting and insulin-antagonising effects of the full GH molecule. Originally developed as a metabolic peptide for adiposity research, AOD-9604’s cardiovascular research relevance derives from the intersection of metabolic and cardiovascular biology: obesity, dyslipidaemia, and visceral adiposity are established cardiovascular risk modifiers, and the mechanisms through which AOD-9604 modulates adipose biology, lipid profiles, and inflammatory state may translate into cardiovascular protection research endpoints.

Beyond its adipose lipolytic biology, emerging preclinical data suggests AOD-9604 may have direct vascular and cardiac actions through mechanisms that partially overlap with GH biology in cardiovascular tissue. This post reviews the mechanistic basis for AOD-9604 cardiovascular research across cardiometabolic endpoints, vascular function, atherosclerosis-relevant biology, and cardiac protection paradigms — a distinct angle from previously published posts covering AOD-9604 adipose and metabolic biology.

AOD-9604 Receptor Biology: GH Fragment Pharmacology

AOD-9604 corresponds to the hGH sequence Tyr-177 to Glu-191 (YLRIVQCRSVEGSCGF with disulphide bond Cys-182–Cys-189), which forms a loop structure that is essential for GH’s interaction with the adipocyte β3-adrenergic receptor. Unlike intact GH, AOD-9604 does not activate the GH receptor (GHR), does not stimulate IGF-1 production, and does not produce insulin-antagonistic IRS-1 Ser-307 phosphorylation — making it a metabolically cleaner lipolytic tool for research.

The β3-adrenergic receptor (ADRB3) pathway is the primary mechanism through which AOD-9604 stimulates adipocyte lipolysis: β3-AR-Gs-adenylyl cyclase-cAMP-PKA-HSL Ser-660 phosphorylation, with PKA also phosphorylating perilipin-1 Ser-497 to release CGI-58 from perilipin sequestration, enabling ATGL-CGI-58 co-activation of triglyceride hydrolysis. In cardiovascular tissue, β3-AR is expressed in cardiomyocytes and vascular smooth muscle cells, where its activation has distinct cardiovascular effects from β1-AR and β2-AR — primarily through NOS-cGMP-PKG signalling in cardiomyocytes (negative inotropic/lusitropic), and vasodilation in vascular smooth muscle (eNOS-mediated via Gi-PI3K-Akt-eNOS Ser-1177).

Whether AOD-9604 activates β3-AR in cardiovascular tissues at concentrations achievable in vivo is a key pharmacological question for cardiovascular research designs. Radioligand binding with [¹²⁵I]-iodocyanopindolol (ICYP, β-blocker) or [³H]-CGP-12177 (β3-AR selective at appropriate concentrations) in cardiac and vascular membrane preparations quantifies β3-AR density and AOD-9604 binding competition.

Cardiometabolic Risk Modification: Dyslipidaemia and Atherogenic Lipid Profile

AOD-9604’s established lipolytic action in visceral adipose tissue produces downstream effects on circulating lipid profiles that are directly relevant to cardiovascular risk biology. Visceral adipose lipolysis increases portal NEFA delivery to the liver, which under conditions of hepatic insulin resistance drives de novo lipogenesis (DNL) and VLDL-TG assembly. However, when AOD-9604-driven lipolysis occurs in the context of fat mass reduction (reducing total adipose triglyceride stores), the net effect on fasting TG, LDL-C, and HDL-C can be favourable — consistent with the established inverse relationship between visceral fat and HDL-C, and positive relationship between visceral fat and TG.

In DIO rodent models, AOD-9604 treatment over 8–12 weeks produces measurable changes in the fasting lipid panel: TG (enzymatic colorimetric; Roche), total cholesterol (TC), HDL-C (precipitation method or direct homogeneous assay), LDL-C (Friedewald equation or direct immunoprecipitation), and VLDL-TG (ultracentrifugation at d<1.006 g/mL). Non-HDL-C (TC − HDL-C) and the TG:HDL-C ratio (atherogenic index of plasma, AIP) provide composite cardiovascular risk readouts. Free fatty acid-binding protein concentrations and apolipoprotein B-100 (quantifying VLDL particle number) provide mechanistic lipid biology readouts.

Lipoprotein particle size by NMR spectroscopy (Vantera platform) or gradient gel electrophoresis distinguishes small, dense LDL-C (pattern B; highest atherogenic risk) from large, buoyant LDL-C (pattern A; lower risk) — an important cardiovascular research endpoint beyond simple LDL-C concentration. GH axis activation, even partial through AOD-9604’s lipolytic mechanism, is associated with shifts from pattern B to pattern A LDL phenotype in obesity research, constituting a quality improvement in the atherogenic lipid profile independent of LDL-C concentration.

Vascular Endothelial Function: eNOS Biology and NO Bioavailability

Endothelial dysfunction — characterised by reduced eNOS Ser-1177 phosphorylation, diminished NO bioavailability, increased superoxide generation from dysfunctional eNOS uncoupling, and elevated VCAM-1/ICAM-1 expression — is an early event in cardiovascular disease pathogenesis, preceding atherosclerotic plaque formation. Obesity-associated inflammation and dyslipidaemia drive endothelial dysfunction through NF-κB-VCAM-1-ICAM-1 upregulation, ROS-mediated eNOS uncoupling (tetrahydrobiopterin [BH4] oxidation, leading to superoxide instead of NO production), and reduced Akt-eNOS phosphorylation downstream of insulin resistance.

AOD-9604’s fat mass-reducing effects in DIO models may indirectly improve endothelial function through adiposity reduction, but the question of direct endothelial biology effects is researchable. Endothelial cells (HUVEC primary culture or EA.hy926 line) treated with palmitate (0.5mM BSA-conjugated) to model lipotoxic endothelial dysfunction can be rescued with AOD-9604 co-treatment, with endpoints including: eNOS Ser-1177 phosphorylation by western blot, intracellular NO production by DAF-FM DA (4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate) fluorescence, VCAM-1 and ICAM-1 surface expression by flow cytometry or ELISA, DCFH-DA ROS generation, and NF-κB p65 nuclear translocation by confocal immunofluorescence.

In vivo vascular function assessment uses wire myography of isolated aortic rings (ACh concentration-response curves for endothelium-dependent relaxation, SNP for endothelium-independent), flow-mediated dilation (FMD) by ultrasound in the femoral artery (mouse femoral artery preparation or rat carotid), and TBAR-MDA lipid peroxidation in aortic tissue. Pulse wave velocity (PWV) measurement by tail-cuff or aortic implanted catheter provides a functional stiffness endpoint relevant to large-artery cardiovascular risk.

Atherosclerosis Research: ApoE⁻/⁻ and LDLR⁻/⁻ Models

ApoE-knockout (ApoE⁻/⁻) mice on Western diet (WD; 21% fat, 0.15% cholesterol, 19.5% casein) develop spontaneous atherosclerotic plaques at the aortic root and descending aorta by 8–12 weeks of feeding, progressing from early foam-cell lesions to fibrous cap plaques by 16–20 weeks. LDLR-knockout (LDLR⁻/⁻) mice on WD develop similar but more slowly progressing lesions. Both models are standard for testing anti-atherosclerotic interventions.

AOD-9604 in ApoE⁻/⁻ WD models provides a research framework for characterising whether the lipid-modifying and adipose-reducing effects of AOD-9604 translate into reduced plaque burden. Primary endpoints include: en face Oil Red O aortic staining (lesion area as % total aortic area), aortic root cross-section Oil Red O lesion area (µm²), macrophage content by CD68 or MAC-2 IHC (foam cell quantification), smooth muscle cell content by α-SMA IHC (fibrous cap), collagen content by Sirius Red/Masson trichrome (plaque stability), necrotic core area (H&E, acellular lipid-rich area), and calcification by Alizarin Red S.

Plasma lipid and inflammatory marker monitoring (TC, TG, HDL-C, LDL-C, VLDL-C, oxLDL by competitive ELISA, MCP-1/CCL2, VCAM-1, E-selectin) at 4-week intervals provides a longitudinal cardiometabolic risk readout during the treatment period. Bone marrow-derived macrophage (BMDM) oxidised-LDL uptake experiments ([³H]-oxLDL or DiI-oxLDL fluorescence; foam cell formation assay in vitro) characterise the direct macrophage biology relevant to foam cell and plaque progression independent of systemic lipid effects.

Cardiac Protection: Ischaemia-Reperfusion Injury

Cardiac ischaemia-reperfusion (I/R) injury — modelled ex vivo by Langendorff perfused isolated heart (20–40 minutes global ischaemia + 60–120 minutes reperfusion) or in vivo by left coronary artery ligation (30 minutes) followed by reperfusion (24 hours to 4 weeks) — produces stereotyped cardiomyocyte death through oxidative burst, mitochondrial permeability transition pore (mPTP) opening, caspase-3 activation, and inflammatory infiltration.

GH and IGF-1 have established cardiac I/R protective effects through Akt-eNOS-NO-sGC-PKG signalling (RISK pathway), which prevents mPTP opening at reperfusion through GSK-3β Ser-9 phosphorylation-mediated mPTP inhibition. Whether AOD-9604 — which lacks full GH receptor activity — can nonetheless exert cardiac I/R protection through β3-AR-NOS-cGMP pathway activation in cardiomyocytes is a testable research hypothesis.

Langendorff cardiac function endpoints include: left ventricular developed pressure (LVDP), heart rate, coronary flow rate, rate-pressure product (RPP = LVDP × HR), LDH release in coronary effluent (cardiomyocyte membrane rupture), infarct size by TTC (2,3,5-triphenyltetrazolium chloride) staining of left ventricular slices (4 slices, 2mm each; infarct%: TTC-negative white area / total LV area). In vivo I/R endpoints include: echocardiographic LVEF, LVFS, LVEDV, and wall motion score at 24h, 1 week, and 4 weeks post-reperfusion; Masson trichrome scar area at 4 weeks; and plasma troponin-I release (ELISA) at 4h and 24h post-reperfusion as a myocardial damage marker.

Mechanistic biochemistry in cardiac I/R includes: Akt Ser-473, GSK-3β Ser-9, eNOS Ser-1177, and ERK1/2 phosphorylation at 15 and 60 minutes post-reperfusion (RISK pathway activation); cytochrome c release from mitochondria (mitochondrial/cytosolic fractionation western blot); caspase-3 p17 cleavage; mitochondrial membrane potential (JC-1 fluorescence ratio in isolated cardiomyocytes); and mPTP opening threshold (calcium-induced swelling spectrophotometry at 540nm in isolated mitochondria).

Hypertension Research: Vascular Remodelling and Stiffness

Obesity-associated hypertension involves multiple mechanisms: increased sympathetic nervous system tone (adipose-derived leptin activating hypothalamic sympathetic outflow), RAAS activation (angiotensin II production elevated by increased adipose angiotensinogen), endothelial dysfunction (reduced NO), and structural vascular remodelling (wall hypertrophy, collagen deposition, elastin fragmentation). AOD-9604’s cardiovascular research relevance in hypertension lies primarily in whether fat mass-dependent reduction in adipose-derived pressor factors translates into blood pressure improvement.

Telemetric blood pressure monitoring (radio-telemetry implants: PhysioTel PA-C40 carotid catheter in DIO rats) provides 24h continuous BP recording without handling stress confound — the gold standard for rodent hypertension phenotyping. Mean arterial pressure (MAP), systolic BP, diastolic BP, pulse pressure, and heart rate across light and dark phases and in response to standardised challenges (saline bolus, phenylephrine, SNP dose-response) characterise the vascular tone profile.

Vascular remodelling is assessed in aortic and mesenteric artery rings by wire myography (active wall tension vs lumen diameter; media:lumen ratio from pressure myography); transmission electron microscopy of aortic media (smooth muscle cell hypertrophy, elastin fragmentation, collagen fibril organisation); and aortic stiffness by ex vivo pressure-diameter relationships (Peterson elastic modulus, incremental elastic modulus). Angiotensin II type-1 receptor (AT1R) density by [¹²⁵I]-Ang II radioligand binding and ACE activity fluorometric assay (Ang I→Ang II conversion) characterise RAAS-vascular interactions.

Inflammatory Cardiovascular Biology: CRP, Adiponectin, and VCAM-1

Systemic low-grade inflammation — elevated hsCRP, IL-6, TNF-α, MCP-1, and sICAM-1 with depressed adiponectin — constitutes the inflammatory cardiometabolic risk profile associated with obesity. AOD-9604-driven visceral fat reduction would be predicted to reduce this pro-inflammatory burden through decreased adipose-derived cytokine production, increased adiponectin (inversely correlated with VAT), and reduced hepatic acute-phase reactant stimulation.

Circulating inflammatory markers measured by Luminex multiplex (IL-6, TNF-α, MCP-1, IL-1β, IFN-γ, IL-10, IL-4) and ELISA (hsCRP, adiponectin total and HMW, sICAM-1, sVCAM-1, E-selectin) provide the systemic cardiometabolic inflammatory profile in DIO models treated with AOD-9604. Adipose tissue-specific inflammatory readouts (CLS F4/80+perilipin IHC, M1:M2 macrophage ratio by flow cytometry, adipose conditioned media cytokine profiling) distinguish adipose-intrinsic from systemic inflammatory changes.

Aortic NF-κB activation (p65 nuclear translocation by IHC, p-IκBα Ser-32 by western blot), VCAM-1 and ICAM-1 protein in aortic homogenate by western blot and ELISA, and monocyte adhesion assay (THP-1 monocyte adhesion to HUVEC monolayer pre-treated with oxidised-LDL or TNF-α with or without AOD-9604 conditioning) characterise vascular inflammatory endpoints relevant to atherosclerosis initiation.

Left Ventricular Hypertrophy and Cardiac Remodelling

Obesity-associated cardiac remodelling includes left ventricular hypertrophy (LVH; concentric in hypertensive obesity, eccentric in volume-overload), diastolic dysfunction (elevated filling pressures, impaired relaxation), and ultimately HFpEF (heart failure with preserved ejection fraction) — a syndrome increasingly prevalent in obese patients. In DIO mouse models at 20–24 weeks of HFD feeding, echocardiographic LVH (increased LVPW and IVS thickness), diastolic dysfunction (elevated E/A ratio reversal, prolonged IVRT, elevated E/e’ by tissue Doppler), and increased LV mass are observed.

AOD-9604 in obese HFpEF models (HFD + L-NAME 0.5g/L drinking water model; or ZSF1 obese rat model; or db/db mouse model) provides a research framework for whether adiposity reduction translates to cardiac structural and functional benefit. LV mass (normalised to tibia length; HW:BW), cardiomyocyte cross-sectional area (CSA on wheat germ agglutinin-stained sections; 100+ cells per animal), interstitial collagen area (Sirius Red automated quantification), LVEDP by Millar catheter, E/A ratio and E/e’ by Doppler echocardiography, and BNP/NT-proBNP plasma ELISA constitute the diastolic dysfunction endpoint battery.

Experimental Design Considerations for AOD-9604 Cardiovascular Research

AOD-9604 cardiovascular research must carefully distinguish direct cardiovascular effects from indirect effects mediated by adipose mass reduction and secondary lipid/inflammatory profile improvement. The design approach requires: 1) pair-feeding controls to isolate the metabolic effect of AOD-9604 from caloric restriction driven by reduced appetite (AOD-9604 is reported not to affect food intake, but pair-fed controls eliminate confounding entirely); 2) body-weight-matched controls (comparing AOD-9604-treated obese to calorie-restriction-matched obese animals normalised to the same body weight) to isolate direct effects from adiposity reduction; and 3) direct in vitro experiments in cardiomyocytes, endothelial cells, and vascular smooth muscle to test receptor-level cardiovascular actions independent of systemic metabolic context.

Appropriate positive controls include: recombinant GH (to test whether full GH receptor-mediated cardiovascular effects exceed AOD-9604 fragment effects), β3-AR agonist CL-316,243 (to test the β3-AR pathway contribution to any observed cardiovascular effects), and orlistat or pair-feeding (as fat-mass-reducing comparators without AOD-9604 pharmacology) to allow attribution of cardiovascular benefit to the specific pharmacological actions of AOD-9604 beyond simple fat loss.

Summary of Key Cardiovascular Research Endpoints for AOD-9604

Key endpoints across AOD-9604 cardiovascular research contexts include: fasting lipid panel (TC, TG, HDL-C, LDL-C, VLDL-C, AIP), LDL particle size NMR/gradient gel, aortic root lesion area Oil Red O and CD68 plaque macrophage IHC (ApoE⁻/⁻ atherosclerosis), wire myography ACh endothelium-dependent relaxation FMD%, eNOS Ser-1177 western blot, DAF-FM NO fluorescence in endothelial cells, Langendorff TTC infarct size%, in vivo LVEF echo post-I/R, telemetric MAP 24h light/dark, Sirius Red vascular media collagen, aortic stiffness Peterson modulus, Luminex systemic inflammatory cytokines, CLS F4/80+perilipin IHC, LV mass/HW:BW/cardiomyocyte CSA, Sirius Red interstitial collagen, E/A and E/e’ diastolic function, Millar LVEDP, BNP/NT-proBNP ELISA.

AOD-9604 cardiovascular research is characterised by the pharmacological advantage of GH-fragment specificity: lipolytic and potentially cardioprotective effects without the insulin-antagonistic and growth-promoting side-effects of intact GH, enabling clean mechanistic dissection of GH-axis cardiovascular biology in metabolic disease contexts.